2008
Subspecializim në hematologji
Fakulteti i Mjekësisë- Shkup

2005
Doktor i shkencave mjekësore
Fakulteti i Mjekësisë, Universiteti në Larisa, Greqi

1998
Specialist në Mjekësi interne
Fakulteti i Mjekësisë- Shkup

1997
Magjistër i shkencave mjekësor- hematologe
Fakulteti i Mjekësisë- Shkup

1989
Fakulteti i Mjekësisë- Shkup

2022
Spitali klinik “Acibadem Sistina”.

2018
Shef i Laboratorit për diagnostifikim hematologjik specifik

1992
ISHP Klinika Universitare për hematologji, Shkup
Mjek i repartit klinik, ambulancës dhe spitalit ditor

Shoqata e hematologëve të Maqedonisë

Anglisht
Spanjisht
Greqisht

1. Evidence for the significant role of immunoglobulin light chains in antigen recognition and selection in chronic lymphocytic leukemia.
Hadzidimitriou A, Darzentas N, Murray F, Smilevska T, Arvaniti E, Tresoldi C, Tsaftaris A, Laoutaris N, Anagnostopoulos A, Davi F, Ghia P, Rosenquist R, Stamatopoulos K, Belessi C.Blood. 2009 Jan 8;113(2):403-11.

2.Chronic lymphocytic leukaemia: an immunobiology approach.
Kostareli E, Smilevska T, Stamatopoulos K, Kouvatsi A, Anagnostopoulos A.
Srp Arh Celok Lek. 2008 May-Jun;136(5-6):319-23. Review.
3. Immunoglobulin kappa gene repertoire and somatic hypermutation patterns in follicular lymphoma.
Smilevska T, Tsakou E, Hadzidimitriou A, Bikos V, Stavroyianni N, Laoutaris N, Fassas A, Alphanagnostopoulos A, Papadaki T, Belessi C, Stamatopoulos K.
Blood Cells Mol Dis. 2008 Sep-Oct;41(2):215-8. Epub 2008 Jul 21
4. Predominantly post-transcriptional regulation of activation molecules in chronic lymphocytic leukemia: the case of transferrin receptors.
Chiotoglou I, Smilevska T, Samara M, Likousi S, Belessi C, Athanasiadou I, Stavroyianni N, Samara S, Laoutaris N, Vamvakopoulos N, Anagnostopoulos A, Fassas A, Stamatopoulos K, Kollia P.
Blood Cells Mol Dis. 2008 Sep-Oct;41(2):203-9.
5. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations.
Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, Belhoul L, Stella S, Stavroyianni N, Crespo M, Hadzidimitriou A, Sutton L, Bosch F, Laoutaris N, Anagnostopoulos A, Montserrat E, Fassas A, Dighiero G, Caligaris-Cappio F, Merle-Béral H, Ghia P, Davi F.
Blood. 2007 Jan 1;109(1):259-70.
6. Immunoglobulin genes in multiple myeloma: expressed and non-expressed repertoires, heavy and light chain pairings and somatic mutation patterns in a series of 101 cases.
Hadzidimitriou A, Stamatopoulos K, Belessi C, Lalayianni C, Stavroyianni N, Smilevska T, Hatzi K, Laoutaris N, Anagnostopoulos A, Kollia P, Fassas A.
Haematologica. 2006 Jun;91(6):781-7.
7. Analysis of expressed and non-expressed IGK locus rearrangements in chronic lymphocytic leukemia.
Belessi C, Stamatopoulos K, Hadzidimitriou A, Hatzi K, Smilevska T, Stavroyianni N, Marantidou F, Paterakis G, Fassas A, Anagnostopoulos A, Laoutaris N.
Mol Med. 2005 Jan-Dec;11(1-12):52-8.
8. Immunoglobulin light chain repertoire in chronic lymphocytic leukemia.
Stamatopoulos K, Belessi C, Hadzidimitriou A, Smilevska T, Kalagiakou E, Hatzi K, Stavroyianni N, Athanasiadou A, Tsompanakou A, Papadaki T, Kokkini G, Paterakis G, Saloum R, Laoutaris N, Anagnostopoulos A, Fassas A.
Blood. 2005 Nov 15;106(10):3575-83.
9. Transferrin receptor-1 and 2 expression in chronic lymphocytic leukemia.
Smilevska T, Stamatopoulos K, Samara M, Belessi C, Tsompanakou A, Paterakis G, Stavroyianni N, Athanasiadou I, Chiotoglou I, Hadzidimitriou A, Athanasiadou A, Douka V, Saloum R, Laoutaris N, Anagnostopoulos A, Fassas A, Stathakis N, Kollia P.
Leuk Res. 2006 Feb;30(2):183-9.
Clinical studies and research :

1. Pharmacokinetics study of Biostate in patients with Haemophilia A

2. Paradigm 2 –a multi-centre, Single-blind trial evaluating safety and efficacy and pharmacokinetics of NNC-0156-0000-0009 when used for treatment and prohylaxis of bleeding episodes in patients with Haemophilia B ( 2012-2014)

3. A phase 3, Randomized,Controlled, Open-label Study of VELCADE (Bortesomib)Melphalan-Prednisone (VMP) compared to Daratumumab in combination with VMP ( D-VMP), in subjecst with previously untreated Multiple myeloma who are ineligible for High-dose Therapy

Mirënjohje nga SHMM dhe mirënjohje nga OMM për kontributin dhe angazhimin në trajtimin e pandemisë së virusit korona